Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial
Cancer, Volume 98, No. 8, Year 2003
Notification
URL copied to clipboard!
Description
BACKGROUND. The goal of the current study was to compare the long-term (25-month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma. METHODS. Patients (n = 1648) were randomized to receive 4 mg or 8 mg (reduced to 4 mg) zoledronic acid as a 15-minute infusion or to receive 90 mg pamidronate as a 2-hour infusion every 3-4 weeks for 24 months. The primary endpoint was the proportion of patients with at least 1 skeletal-related event (SRE), defined as pathologic fracture, spinal cord compression, radiation therapy, or surgery to bone. Secondary analyses included time to first SRE, skeletal morbidity rate, and multiple-event analysis. Hypercalcemia of malignancy (HCM) was included as an SRE in some secondary analyses. RESULTS. After 25 months of follow-up, zoledronic acid reduced the overall proportion of patients with an SRE and reduced the skeletal morbidity rate similar to pamidronate. Compared with pamidronate, zoledronic acid (4 mg) reduced the overall risk of developing skeletal complications (including HCM) by an additional 16% (P = 0.030). In patients with breast carcinoma, zoledronic acid (4 mg) was significantly more effective than pamidronate, reducing the risk of SREs by an additional 20% (P = 0.025) compared with pamidronate and by an additional 30% in patients receiving hormonal therapy (P = 0.009). Zoledronic acid (4 mg) and pamidronate were tolerated equally well. The most common adverse events included bone pain, nausea, and fatigue. CONCLUSIONS. Long-term follow-up data confirm that zoledronic acid was more effective than pamidronate in reducing the risk of skeletal complications in patients with bone metastases from breast carcinoma and was of similar efficacy in patients with multiple myeloma. © 2003 American Cancer Society.
Authors & Co-Authors
Rosen, Lee S.
United States, Santa Monica
Cancer Institute Medical Group
Gordon, David H.
United States, San Antonio
Division of Hematology and Medical Oncology
Kaminski, Mary
United States, Kennesaw
American Medical Research Institute
Howell, Anthony H.
United Kingdom, Manchester
The Christie Nhs Foundation Trust
Belch, Andrew R.
Canada, Edmonton
University of Alberta
Mackey, John R.
Canada, Edmonton
University of Alberta
Apffelstaedt, Justus P.A.
South Africa, Tygerberg
Tygerberg Hospital
Hussein, Mohamad
United States, Cleveland
Cleveland Clinic Foundation
Coleman, RE E.
United Kingdom, Sheffield
Weston Park Cancer Centre
Reitsma, Dirk J.
Switzerland, Basel
Novartis International ag
Chen, Bee Lian
Switzerland, Basel
Novartis International ag
Seaman, John J.
Switzerland, Basel
Novartis International ag
Statistics
Citations: 709
Authors: 12
Affiliations: 9
Identifiers
Doi:
10.1002/cncr.11701
ISSN:
0008543X
Research Areas
Cancer
Disability
Health System And Policy
Study Design
Cohort Study